The Nutrient Formula Containing Eicosapentaenoic Acid and Docosahexaenoic Acid Benefits the Fatty Acid Status of Patients Receiving Long-Term Enteral Nutrition
The Nutrient Formula Containing Eicosapentaenoic Acid and Docosahexaenoic Acid Benefits the Fatty Acid Status of Patients Receiving Long-Term Enteral Nutrition
复制标题
DOI：
10.1620/tjem.217.23
复制
发表时间：
2009-01-01
影响因子：
2.2
通讯作者：
Onuma, Akira
中科院分区：
文献类型：
--
作者：
Munakata, Mitsutoshi;Nishikawa, Masazumi;Onuma, Akira
目前，具有不同脂肪酸组成的各种配方用于肠内营养（EN）。所有配方奶粉均含有不同浓度的必需脂肪酸：亚油酸（LA）和α-亚麻酸（ALA）; LA在体内生物转化为花生四烯酸（AA），ALA转化为二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）。一些配方含有预制的EPA和DHA。然而，脂肪酸组成的差异对长期EN患者脂肪酸状态的影响尚不清楚。我们测定了50例接受长期EN治疗的神经系统疾病患者的血清脂肪酸浓度。然后回顾性地比较数据，参考所使用的配方的脂肪酸组成。所有患者均通过EN接受几乎全部营养摄入至少1年。在注射EN溶液前采集血样。在不含EPA或DHA的配方奶粉中，ALA浓度低的配方奶粉与低血清EPA和DHA相关。相反，具有降低的LA浓度的富含ALA的配方显著增加了EPA和DHA水平，尽管水平仍然低于对照值。在含有EPA和DHA的配方中，EPA和DHA水平达到对照值。因此，EN配方的脂肪酸组成影响接受长期EN的患者的脂肪酸状态。含有预制EPA和DHA以及适量必需脂肪酸的配方可能对这些患者有益。
Currently, various formulas with different fatty acid compositions are used for enteral nutrition (EN). All formulas contain various concentrations of essential fatty acids: linoleic acid (LA) and alpha-linolenic acid (ALA); LA is biotransformed into arachidonic acid (AA) and ALA into eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in vivo. Some formulas contain preformed EPA and DHA. However, the effects of the differences in the fatty acid composition on the fatty acid status of patients receiving long-term EN is not clear. We measured serum fatty acid concentrations in 50 patients with neurological diseases receiving long-term EN. The data were then compared retrospectively with reference to the fatty acid compositions of the formulas used. All of the patients received almost their entire nutritional intake via EN for at least 1 year. Blood samples were obtained just before injecting the EN solution. Among the formulas that did not include EPA or DHA, formulas with low ALA concentrations were associated with low serum EPA and DHA. Conversely, the ALA-enriched formulas with reduced LA concentrations significantly increased EPA and DHA levels, although the levels remained lower than the control values. With the formula containing EPA and DHA, the EPA and DHA levels reached control values. Therefore, the fatty acid composition of the EN formulas affected the fatty acid status of patients receiving long-term EN. Formulas containing preformed EPA and DHA with suitable amounts of essential fatty acids may benefit these patients.